IRCT20180815040801N1 IRCT 2019-02-06 Tehran University of Medical Sciences The Effect of Capecitabine and Cisplatin as a Radiosensitizer in Radiation of Bladder Cancer Assessment of Tolerability, Response and Complications of Capecitabin added to Cisplatine for Concurrent Chemoradiation of Muscle Invasive Bladder Cancer 2018-01-20 anticipated 25 Complete https://irct.ir/trial/34249 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 1-2 Bladder cancer. Intervention group: Patients with muscle invasive bladder cancer at T2-T4aN0M0 stage referring to Department of Radiation Oncology Cancer Institute. In this study, 25 patients with Transitional Cell Carcinoma (TCC), stage T2-T4a who are candidates for radical cystectomy but refuse the surgery would be evaluated. First, the urologist resect the tumor as far as possible by the transuretral resection method, and then refer the patient for chemoradiation. For all the patients the standard questionnaire CTCAE4.03 2010 would be filled . The patients would be CT simulated and contoured. Then the best plan would be chosen according to contouring with the total dose of 66 Gy in 33 fractions. Concurrently Cisplatin 35 mg per m2 weekly and Capecitabine 625 mg per m2 twice a day except holidays would be prescribed. During the treatment CBC, Diff, BUN, Cr would be checked weekly. The standard questionnaire CTCAE4.03 2010 would be filled weekly, last day of radiation and 3 months after the treatmant. Three months after the end of the treatment, cystoscopy and biopsy from the tumor bed and urine cytology would be repeated. Complete clinical response is defined as the absence of a tumor in the cystoscopy, a negative biopsy of the tumor site and the absence of cells Tumor in urine cytology. No - There is not a plan to make this available Justification or reason for not sharing IPD is Data of other research maybe become at risk